Titlesort descending Trial description Contact name Trial end date Trial start date Trial tumour type
ARTIST ‘ARTIST’ stands for a translational research Approach to development of optimal Renal cancer Treatments In Surgical and systemic Therapy patients, a single-centre translational research study designed to identify and characterize novel biomarkers for the optimal detection, monitoring and treatment of renal cell cancer (RCC). Dr James Jones 31 Dec 2025 4 Jan 2021 Kidney
BEAT-meso A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma Dr David Gilligan 15 Jan 2025 5 Sep 2019 Lung
Best-Of Phase III study assessing the "Best-Of" radiotherapy compared to the "Best-Of" surgery (trans-oral surgery (TOS) in patients with T1-T2, N0 oropharyngeal carcinoma Dr Ekpemi Irune 1 Jan 2026 17 Nov 2020 Head & neck
CompARE Trial Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer Dr Rashmi Jadon 31 Jan 2026 5 Mar 2019 Head & neck
COSI An International Randomised Clinical Trial of Therapeutic Interventions with the Potential to Improve Outcome in Adults with Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation Dr Charles Crawley 1 Apr 2025 9 Sep 2020 Haematological
COSMIC-313 A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk Dr Kate Fife 1 Mar 2025 6 Dec 2019 Kidney
EMBRACE-II Image guided intensity modulated External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer Dr Li Tee Tan 30 Jun 2024 7 Nov 2017 Gynaecological
FLAURA-2 A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA-2) Dr Gary Doherty 23 Mar 2026 25 Sep 2020 Lung
KEYNOTE-641 A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Dr Danish Mazhar 30 Apr 2024 8 Oct 2019 Prostate
LEAP-006 A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006) Dr Gary Doherty 30 Sep 2024 18 Sep 2020 Lung
MITRE Microbiome Immunotherapy Toxicity and Response Evaluation (MITRE) An observational study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy Dr Pippa Corrie 8 Jul 2025 30 Mar 2021 Lung, Kidney, Skin & melanoma
PACE-C International randomised study of prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for organ-confined prostate cancer Dr Alex Martin 26 Apr 2026 5 Feb 2020 Prostate
Pharmacyclics PCYC 1141 (Bruton's Tyrosine Kinase Inhibitor, Treatment for Follicular Lymphoma) A Multicentre, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma Dr George Follows 16 Mar 2025 27 Jul 2018 Haematological
ROAM Radiation versus observation following surgical resection of atypical meningioma: A randomised controlled trial Dr Sarah Jefferies 30 Apr 2025 17 Nov 2016 Brain and CNS
SKYSCRAPER-07 A phase III randomised , double-blind, placebo-controlled study of Atezolizumab with or without Tiragolumab (anti-tigit antibody) in patients with locally advanced esophageal squamous cell carcinoma Dr Lizzie Smyth 31 Dec 2025 17 Nov 2020 Oesophageal
WIRE ‘WIRE’ stands for WIndow-of-opportunity clinical trial platform for evaluation of novel treatment strategies in REnal cell cancer, a clinical trial that makes opportunistic investigational use of the existing 4-week surgical window-of-opportunity between the decision to operate on surgically resectable renal cell cancer (RCC) and surgery itself. Professor Grant Stewart 31 Jan 2025 28 Aug 2020 Kidney